高剂量与标准剂量流感疫苗对住院的保护效果:DANFLU-2试验按衰弱风险的预设分析
BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults ag…
核心结论
- 在丹麦65岁及以上成人中,衰弱风险可能修饰高剂量与标准剂量灭活流感疫苗对流感或肺炎住院的相对效果,衰弱风险越高rVE估计值越大。
- 但预设分类亚组未显示效应修饰,亚组估计不精确且95%CI跨越无效线,结果应视为探索性。
研究设计与样本
- DANFLU-2是一项开放标签、个体随机试验的预设分析,在丹麦连续三个流感季(2022-23、2023-24、2024-25)开展。
- 衰弱按随机化前10年内ICD-10编码计算的医院衰弱风险评分(HFRS)定义,分为低(<5分)、中(5-15分)、高(>15分)三层。
关键数值与推荐
- 衰弱分层标准:HFRS低风险<5分、中风险5-15分、高风险>15分。
- 主要终点:流感或肺炎住院。
- 相对疫苗效果(rVE)按预设HFRS分类及HFRS连续变量评估。
临床怎么用
- 对衰弱风险较高的65岁及以上成人,可考虑选用高剂量流感疫苗以降低流感或肺炎住院风险。
- 应告知患者当前证据为探索性,亚组估计不精确,需进一步研究验证。
局限性
- 作者指出结果应视为探索性,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332 438 randomised participants (mean age 73·7 years [SD 5·8]; 161 538 [48·6%] were female), 276 173 (83·1%) had low frailty risk, 52 395 (15·8%) had intermediate frailty risk, and 3861 (1·2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0·5%) of 276 173 participants with low frailty risk, 761 (1·5%) of 52 395 with intermediate frailty risk, and 163 (4·2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2·8 [95% CI 2·6-3·1]; RR for high vs low frailty risk 8·2 [7·0-9·6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0·020). The rVE was 0·2% (95% CI -10·8 to 10·2) among those with low frailty risk, 13·1% (-0·4 to 24·8) among those with intermediate frailty risk, and 19·9% (-10·3 to 42·1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0·17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13 366 [4·8%] of 275 795 for low frailty risk, 5475 [10·5%] of 52 315 for intermediate frailty risk, and 777 [20·2%] of 3850 for high frailty risk; p<0·0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.
引用
- Espersen C, Johansen ND, Modin D, et al. Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2. Lancet Healthy Longev. 2026. PMID: 42753782. doi:10.1016/j.lanhl.2026.100894
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。